Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its portfoilio.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Though Isomorphic is burning through millions in R&D costs now, investors have high hopes for the potential of AI drug development.
The leadership change comes as the retail pharmacy industry faces thin profit margins, store closures, and layoffs.
After nearly 3,000 years, the business of the Olympics is ripe for disruption. Could performance enhancing drugs shake up the games?
The Department of Health announced this week that Medicare is cutting prices for dozens of prescription drugs that have outpaced inflation.